BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|April 8, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-05-04-2016
- Volume 11
- Issue 5
WellSpring Pharma Services Completes Capital Investment and Forms Strategic Partnership
Author(s)Pharmaceutical Technology Editors
WellSpring Pharma formed a strategic partnership with IDT Australia and invested $3 million in new equipment.
Advertisement
WellSpring Pharma Services announced a $3 million capital investment in equipment and a strategic partnership with IDT Australia to manufacture drugs targeting the US market. According to an April 7, 2016 press announcement, the capital investment enables directly scalable capabilities in smaller development-scale equipment, expanded manufacturing for specialized dosage forms such as bilayer tablets, and improved support for high-potency compound manufacturing.
Among the equipment added during the capitalization were an Alexanderwerk Roller Compactor, an IMA Precisa capsule weight checker, a 400 kg O’Hara Tray Drying oven, a Korsch XL 400 Tablet Press with bilayer module, a Glatt GPCG 2/5 Fluid Bed Processor, an O’Hara Aqueous Film Coater with 18” and 30” interchangeable pans, and a 5L Becomix Counter sweep vessel.
Source:
Articles in this issue
over 10 years ago
Formulation and CTM Demand Drives Expansion and Consolidationover 10 years ago
ADCs Challenge Manufacturers’ Skill Setsover 10 years ago
Technology Drives Shipping Risk Managementover 10 years ago
Tracking Pharma’s Serialization Effortsover 10 years ago
PPD Appoints Vice-President of Central Laboratory Developmentover 10 years ago
Frankfurt May Become Europe’s Largest Certified Pharma Hubover 10 years ago
Quotient Clinical Extends Spray Drying Capabilitiesover 10 years ago
Cryoport Enters Strategic Partnership with Worthington Industriesover 10 years ago
Almac Partners with Optel to Launch Serialization SolutionAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
5